loading
Schlusskurs vom Vortag:
$474.00
Offen:
$477.66
24-Stunden-Volumen:
606.82K
Relative Volume:
0.52
Marktkapitalisierung:
$61.09B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-188.91
EPS:
-2.4669
Netto-Cashflow:
$-52.09M
1W Leistung:
-0.90%
1M Leistung:
+1.55%
6M Leistung:
+96.85%
1J Leistung:
+57.19%
1-Tages-Spanne:
Value
$461.21
$480.53
1-Wochen-Bereich:
Value
$461.21
$495.55
52-Wochen-Spanne:
Value
$205.87
$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Firmenname
Alnylam Pharmaceuticals Inc
Name
Telefon
(617) 551-8200
Name
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Mitarbeiter
2,230
Name
Twitter
@alnylam
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
466.08 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.28 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.01 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.60 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.98 34.68B 4.56B -176.77M 225.30M -1.7177

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-04 Hochstufung Oppenheimer Perform → Outperform
2025-08-04 Hochstufung Wolfe Research Underperform → Peer Perform
2025-07-30 Fortgesetzt Raymond James Outperform
2025-07-21 Eingeleitet Truist Buy
2025-03-31 Eingeleitet Redburn Atlantic Buy
2025-03-24 Hochstufung JP Morgan Neutral → Overweight
2024-11-12 Herabstufung Wolfe Research Peer Perform → Underperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-16 Hochstufung Goldman Neutral → Buy
2024-02-16 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-08 Eingeleitet Wells Fargo Equal Weight
2023-10-11 Herabstufung Oppenheimer Outperform → Perform
2023-09-29 Eingeleitet Raymond James Outperform
2023-05-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-26 Eingeleitet SMBC Nikko Neutral
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Buy
2022-09-09 Fortgesetzt Morgan Stanley Equal-Weight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-27 Herabstufung Guggenheim Buy → Neutral
2022-06-07 Eingeleitet William Blair Outperform
2022-04-25 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-03-01 Eingeleitet Citigroup Buy
2022-02-03 Hochstufung Guggenheim Neutral → Buy
2022-01-03 Hochstufung Piper Sandler Neutral → Overweight
2021-11-22 Hochstufung Goldman Neutral → Buy
2021-11-22 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Hochstufung Oppenheimer Perform → Outperform
2021-10-04 Hochstufung UBS Neutral → Buy
2021-08-04 Herabstufung Piper Sandler Overweight → Neutral
2021-02-22 Herabstufung Guggenheim Buy → Neutral
2021-02-12 Herabstufung Citigroup Buy → Neutral
2021-02-12 Bestätigt H.C. Wainwright Buy
2021-01-25 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-09-30 Fortgesetzt Berenberg Hold
2020-09-08 Eingeleitet Citigroup Buy
2020-08-11 Herabstufung Oppenheimer Outperform → Perform
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2020-05-07 Herabstufung JP Morgan Overweight → Neutral
2020-04-24 Fortgesetzt Evercore ISI Outperform
2020-03-19 Eingeleitet Berenberg Buy
2019-12-19 Bestätigt Chardan Capital Markets Buy
2019-11-20 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-06 Hochstufung Evercore ISI In-line → Outperform
2019-03-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-01-23 Eingeleitet UBS Neutral
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-13 Bestätigt Stifel Buy
2018-08-07 Hochstufung Stifel Hold → Buy
2018-05-04 Bestätigt Stifel Hold
2018-03-28 Eingeleitet Evercore ISI In-line
Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

pulisher
07:32 AM

Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com

07:32 AM
pulisher
07:13 AM

What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Retail & Safe Capital Investment Plans - newser.com

07:13 AM
pulisher
02:26 AM

Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Market Outlook & Daily Stock Momentum Reports - newser.com

02:26 AM
pulisher
Oct 21, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesInflation Watch & Long Hold Capital Preservation Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 18:00:20 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 15:17:29 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Are Alnylam Shares Still Attractive After a 110% Surge and Fresh Pipeline News? - simplywall.st

Oct 21, 2025
pulisher
Oct 21, 2025

Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025Trend Reversal & Risk Adjusted Buy/Sell Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryMarket Risk Report & Long-Term Growth Stock Strategies - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is it time to cut losses on Alnylam Pharmaceuticals Inc.Weekly Profit Report & Community Verified Trade Signals - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How to recover losses in Alnylam Pharmaceuticals Inc. stockPortfolio Performance Summary & Weekly High Potential Stock Alerts - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratios2025 Volatility Report & Growth Focused Entry Point Reports - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Why Alnylam (ALNY) Might be Well Poised for a Surge - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Navigating Growth Amidst a Potential -5.64% Downside - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 20, 2025

News impact scoring models applied to Alnylam Pharmaceuticals Inc.2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Strong Pipeline Momentum - simplywall.st

Oct 19, 2025
pulisher
Oct 19, 2025

What drives Imagi International Holdings Limited BOI7 stock priceShort-Term Trading Alerts & Affordable Investment Strategies - earlytimes.in

Oct 19, 2025
pulisher
Oct 18, 2025

Why Alnylam Pharmaceuticals Inc. stock is recommended by analysts2025 Trading Recap & Growth Focused Entry Reports - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

Alnylam price target raised to $535 from $459 at Truist - Yahoo Finance

Oct 18, 2025
pulisher
Oct 18, 2025

Is Alnylam Pharmaceuticals Inc. stock ready for breakout2025 Pullback Review & Safe Entry Momentum Stock Tips - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Patterns & Growth Oriented Trade Recommendations - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Truist Securities Raises Price Target for Alnylam Pharmaceuticals (ALNY) by 16.56% | ALNY Stock News - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Alnylam stock price target raised to $535 from $459 by Truist Securities - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results - BioSpace

Oct 17, 2025
pulisher
Oct 16, 2025

Alnylam Pharmaceuticals Hits New 52-Week High of $485.28 - Markets Mojo

Oct 16, 2025
pulisher
Oct 16, 2025

Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New Partnerships, Pipeline Progress, and Fresh Financing - Yahoo Finance

Oct 16, 2025
pulisher
Oct 16, 2025

Responsive Playbooks and the ALNY Inflection - news.stocktradersdaily.com

Oct 16, 2025
pulisher
Oct 16, 2025

Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - sharewise.com

Oct 16, 2025
pulisher
Oct 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD By Investing.com - Investing.com Nigeria

Oct 15, 2025
pulisher
Oct 15, 2025

Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD - Investing.com

Oct 15, 2025
pulisher
Oct 15, 2025

What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals? - Yahoo Finance

Oct 15, 2025
pulisher
Oct 14, 2025

The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st

Oct 14, 2025

Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Greenstreet Yvonne
Chief Executive Officer
Oct 02 '25
Sale
452.05
8,924
4,034,085
65,409
Tanguler Tolga
EVP, Chief Commercial Officer
Oct 02 '25
Sale
452.05
1,405
635,126
27,438
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Oct 02 '25
Sale
452.05
2,441
1,103,451
25,231
Garg Pushkal
EVP Chief R&D
Oct 03 '25
Sale
451.48
3,022
1,364,387
20,221
Garg Pushkal
EVP Chief R&D
Oct 02 '25
Sale
452.05
2,937
1,327,675
23,243
$582.32
price up icon 0.43%
$817.48
price down icon 2.09%
biotechnology ONC
$313.98
price down icon 0.56%
$160.70
price down icon 2.79%
$105.68
price down icon 1.17%
Kapitalisierung:     |  Volumen (24h):